Background: Poly(methyl methacrylate) (PMMA) bone cement is widely used in cementedarthroplasties. One shortcoming of the cement is its high value of the maximum temperature reachedduring polymerization (Tmax), which, it has been postulated, plays a role in various deleterious phenomena such as thermal necrosis of peri-prosthetic tissues.Purpose: This was to use the results of an investigation of the influence of one modification of thecomposition of the powder (addition of a phase-change material (PCM)) of a commercially-availablegentamicin-loaded PMMA bone cement and one modification of the liquid of the cement (a chainstopping agent (CSA)) on Tmax and 10 other clinically-relevant properties of the cement to identify experimental cement formulation(s) that warrant(s) further evaluation as possible alternative(s) to thecontrol cement.Materials and Methods: The PCM was microencapsulated paraffin (MEPAR) (5, 15, and 25wt./wt.%) and the CSA was (1-dodecyl mercaptan (DDM) (1, 2, and 3 vol./vol.) Other cement properties determined included doughing time (tdough), setting time (tset), compressive strength (σc), radiopacity, and amount of gentamicin eluted.Results: Relative to the value for the control cement, Tmax for each experimental cement formulationwas significantly lower, but the changes in the other properties varied from significant to insignificant.An outcome of the application of a validated materials selection methodology to the collection ofproperty results led to a ranking of the experimental cement formulations.Conclusion: The formulation in which 2 or 3 vol./vol.% DDM was added to the cement liquid shouldbe evaluated further as possible alternatives to the control cement.
展开▼
